Skip to content
HowShorted

ROCKET PHARMACEUTICALS, INC. short interest in 2022

In 2022, ROCKET PHARMACEUTICALS, INC.'s disclosed short interest ran from 13.35% of shares outstanding on 14 Jan 2022 to 9.30% on 30 Dec 2022, a change of -4.05 percentage points. The year's high was 17.80% on 15 Sep 2022 and its low 9.29% on 15 Dec 2022, averaging 13.06% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.03 days on 14 Apr 2022. Full history: ROCKET PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ROCKET PHARMACEUTICALS, INC. in 2022

2022 in figures

Start of year
13.35% (14 Jan 2022)
End of year
9.30% (30 Dec 2022)
Change
-4.05 pp
High
17.80% (15 Sep 2022)
Low
9.29% (15 Dec 2022)
Average
13.06%
Highest days to cover
25.03 (14 Apr 2022)
SEC filings marked
7

Every report in 2022

ROCKET PHARMACEUTICALS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202213.35%15.44
31 Jan 202212.13%15.72
15 Feb 202212.68%14.84
28 Feb 202212.83%20.26results (8-K), 10-K filed
15 Mar 202213.09%15.53
31 Mar 202213.60%24.75
14 Apr 202213.42%25.03
29 Apr 202211.73%12.37
13 May 202211.45%8.5610-Q filed
31 May 202212.61%7.51
15 Jun 202212.03%9.03
30 Jun 202212.54%8.24
15 Jul 202213.04%9.48
29 Jul 202213.71%13.01
15 Aug 202216.26%14.75results (8-K), 10-Q filed
31 Aug 202216.45%18.95
15 Sep 202217.80%10.53
30 Sep 202217.11%7.86
14 Oct 202214.32%7.55
31 Oct 202214.24%12.48
15 Nov 202210.32%9.42results (8-K), 10-Q filed
30 Nov 202210.08%11.29
15 Dec 20229.29%7.50
30 Dec 20229.30%4.81

See also: ROCKET PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.